Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.
about
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocritGenotype-guided tacrolimus dosing in African-American kidney transplant recipients.CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism.Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.CYP3A activity: towards dose adaptation to the individual.Genetic predictors of long-term graft function in kidney and pancreas transplant patients.Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation.Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients.Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.
P2860
Q33628473-874DF8A3-F739-44CF-B099-75E9706A07BCQ35016679-DA3DE1DC-ADE8-4319-B9B3-6C166BAE71A0Q36072508-901D3376-8F7B-4605-B969-A16272C6D270Q37009025-951BFF95-4B56-4AF9-A611-9ABEFF1E760DQ38702659-52340EF4-70CB-48BC-9F9E-A60F6D172888Q38748975-D5A0107C-2EAD-41C3-911F-1D4976793DCDQ38763583-F5DC9BD7-464A-4055-B1F2-D1F1E4D224BCQ38767421-7D4295AC-D4AD-45E0-90E0-FB54E18D487EQ41566058-E6714258-15BE-4D4F-B8F3-CB2A07DA2B7DQ47400761-00D049AF-B997-4988-AA44-9F12ABBB742CQ47803890-C5A31886-4FBA-4E23-B15F-780E71FD8333Q48295034-F5FA0E90-C47E-4DC8-B2AB-F15B195F92DA
P2860
Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Impact of CYP3A5 genotype on t ...... P3A5-mediated drug metabolism.
@en
Impact of CYP3A5 genotype on t ...... P3A5-mediated drug metabolism.
@nl
type
label
Impact of CYP3A5 genotype on t ...... P3A5-mediated drug metabolism.
@en
Impact of CYP3A5 genotype on t ...... P3A5-mediated drug metabolism.
@nl
prefLabel
Impact of CYP3A5 genotype on t ...... P3A5-mediated drug metabolism.
@en
Impact of CYP3A5 genotype on t ...... P3A5-mediated drug metabolism.
@nl
P2093
P2860
P356
P1433
P1476
Impact of CYP3A5 genotype on t ...... P3A5-mediated drug metabolism.
@en
P2093
Dirk R J Kuypers
Hylke de Jonge
Yves Vanrenterghem
P2860
P304
P356
10.2217/PGS.13.133
P577
2013-09-01T00:00:00Z